Because of the health crisis linked to the COVID-19 (coronavirus) epidemic currently affecting France, the Government has decided to impose strict containment measures throughout the country. LAPROVET of course supports this decision, which should help to contain the current epidemic and guarantee the safety of everyone, starting with its collaborators. In this context, orders and […]
H9N2 virus is a low pathogenic subtype of Avian Influenza. Initially discovered in South-East Asia, it was then identified in the Middle East and Egypt (2011), before migrating to Morocco and Tunisia (2016); it is now continuing its extension to West Africa since it has been identified in several countries in the area since 2017. […]
Before they can be marketed through the network of authorised professionals, veterinary medicinal products are subject to a Marketing Authorisation (MA), as are human medicinal products.
It has been demonstrated that poultry farm in villages is a viable alternative source of income for rural households. The Newcastle disease constitutes a major obstacle to develop and maintain these farms; it is therefore important to combat this virus through preventive vaccination campaigns. Through a field approach, LAPROVET is actively involved against this disease […]
Follow all LAPROVET news on Facebook, Linkedin and Twitter!
Interview of Dr Guillaume REMOND, LAPROVET’s Managing Director, which describe the strategic positioning and vision of the company during the VIV Bangkok in March 2015
Manufacturing site of LAPROVET’s Trypanocidals (Securidium & Survidim).